CD274 and hepatocellular carcinoma: Although patients who respond to immunotherapy tend to be those that benefit most in terms of survival,23 evolving experience in the use of PD‐(L)1 inhibitors in indications other than HCC suggests the potential for treatment‐induced benefit even in those patients who fail to achieve a significant radiological response; a finding that does not apply to TKIs.